Hematide
Hematide Uses, Dosage, Side Effects, Food Interaction and all others data.
Hematide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. Hematide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and β-alanine. FDA approved March 27, 2012.
Hematide increases the reticulocyte count and levels of hemoglobin. It also increases RBC count, hematocrit, and soluble transferrin receptor protein in a dose-dependent manner.
| Trade Name | Hematide |
| Availability | Discontinued |
| Generic | Peginesatide |
| Peginesatide Other Names | Hematide, Peginesatide |
| Related Drugs | ferrous sulfate, Aranesp, Epogen, epoetin alfa |
| Type | |
| Protein binding | Peginesatide does not bind to serum albumin or lipoprotein as demonstrated in in-vitro studies. |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Hematide is used for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis
How Hematide works
Hematide binds to and activates the human erythropoietin receptor and stimulates erythropoiesis in human red cell precursors in vitro.
Toxicity
The most common adverse events (≥10%) are dyspnea, diarrhea, nausea, cough, and arteriovenous fistula site complication.
Hematide Drug Interaction
Volume of Distribution
IV dose, dialysis patients = 34.9 ± 13.8 mL/kg;
Elimination Route
Tmax, SubQ dose = 48 hours;
Bioavailability, SubQ dose = 46%;
Hematide does not accumulate when administered every 4 weeks following intravenous or subcutaneous administration.
Half Life
IV dose, healthy subjects = 25.0 ± 7.6 hours; SubQ, healthy subjects = 53.0 ± 17.7 hours; IV dose, dialysis patients = 47.9 ± 16.5 hours;
Clearance
Systemic clearance, IV dose, dialysis patients = 0.5 ± 0.2 mL/hr•kg
Elimination Route
Hematide administered intravenously or subcutaneously is primarily excreted via urine. Most of the excreted dose is in the form of unchanged drug. Elimination from the plasma is biphasic and rapid from vascular compartments. In contrast, the drug is selectively retained in sites of erythropoiesis like the bone marrow.
Innovators Monograph
You find simplified version here Hematide
